It is known that during the progress of diabetes and obesity through high fat diet in experimental rodent models, the development of autonomic neuropathy occurs, which could alter the gut-brain axis and the enteric GLP-1 signal, consequently hampering the therapeutic efficacy of DPP4 inhibitors [12]. This evidence concerns the gene GCG and autonomic neuropathy.